ESTRO 2024 - Abstract Book

S2474

Clinical - Urology

ESTRO 2024

Conclusion:

Delivering a focal SIB to the DIL for unfavorable intermediate to high-risk prostate cancer patients resulted in favorable oncologic outcomes and acceptable toxicity profiles. The mean IPSS and IPSS-QOL scores both worsened during treatment; however, both scores returned to the baseline level by 3 months and remained sustained until 4 years after treatment.

Keywords: DIL boost, prostate cancer, quality of life

References:

1.Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Kollmeier M, et al. Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer. J Urol. 2015;194(6):1624-30. 2.Pucar D, Hricak H, Shukla-Dave A, Kuroiwa K, Drobnjak M, Eastham J, et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step section pathology evidence. Int J Radiat Oncol Biol Phys. 2007;69(1):62-9. 3.Mendez LC, Ravi A, Chung H, Tseng CL, Wronski M, Paudel M, et al. Pattern of relapse and dose received by the recurrent intraprostatic nodule in low- to intermediate-risk prostate cancer treated with single fraction 19 Gy high dose-rate brachytherapy. Brachytherapy. 2018;17(2):291-7.

4.Chopra S, Toi A, Taback N, Evans A, Haider MA, Milosevic M, et al. Pathological predictors for site of local recurrence after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82(3):e441-8.